Other Proteins

Recombinant human KRAS (GTPase), isoform a, encompassing amino acids 2-186 (end). In this construct the N-terminal end of the protein contains a His-tag (6xHis) followed by an optimal TEV protease target sequence that allows cleavage of the His-tag from the protein (TEV: tobacco etch virus cysteine protease BPS Bioscience #50308). The protein also contains mutation of interest G12D. The protein was affinity purified and was loaded with BODIPY-GDP. Unbound BODIPY-GDP was removed by spin column and the protein is ready for a GDP/GTP exchange assay

Severe acute respiratory Coronavirus Spike trimer (S1+S2), Genbank Accession No. MN908947, a.a. 16-1213, with a with C-terminal His-tag, Eu-labeled, expressed in a HEK293 expression system. MW=139 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

iFluor-488-labeled SARS-CoV-2 Spike S1 (a.a. 16-685, with C-terminal Avi-His-Tag. MW = 78 kDa + glycans

Canine CD38 (Genbank #NM_001003143, a.a. 44-308(end), with C-terminal His tag, expressed in HEK293 cells. MW = 31 kDa.

Recombinant SARS-CoV-2 Nucleocapsid protein (N protein), full length, encompassing amino acids 1-419(end). This protein corresponds to SARS-CoV-2 Variant B.1.1.7 originally discovered in the United Kingdom, and contains mutations D3L, R203K, G204R, and S235F. It also contains a C-terminal Avi-Tag™ and a C-terminal His-tag. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification.

Recombinant SARS-CoV-2 Nucleocapsid protein (N protein), full length, encompassing amino acids 1-419(end), plus a C-terminal Avi-tag™ and a C-terminal His-tag. This protein corresponds to SARS-CoV-2 Variant P.1 originally discovered in Brazil and contains the mutation P80R.

Recombinant human CD19 encompassing amino acids 21-291. This construct contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis). The recombinant protein was affinity purified.

This purified rabbit monoclonal antibody recognizes recombinant wildtype SARS-CoV-2 Spike RBD and trimeric spike proteins. Additionally, this antibody cross-reacts with the B.1.1.7 variant, originally discovered in the U.K, and the B.1.351 variant, originally discovered in South Africa, for both the Spike RBD and trimeric proteins. This neutralizing antibody impedes the interaction between SARS-CoV-2 spike proteins and ACE2 receptor. ACE2 receptor is known to mediate COVID-19 infection through direct binding of the SARS-CoV2 Spike protein. This neutralizing antibody has been functionally tested using BPS Bioscience Spike RBD: ACE2 Inhibitor Screening Kits (BPS Bioscience, #78018, #78133, #78152). This antibody not been tested for cross reactivity with other SARS-CoV-2 variants.

Recombinant human B cell receptor CD22 encompassing amino acids 20-464. This protein is fused in C-terminal with the Fc fragment of human IgG1 followed by a C-terminal Avi-Tag™. The recombinant protein was affinity purified and labeled with PE.